Login / Signup
Darrel Francis speaks to Faiez Zannad about his meta-analysis of SGLT2 inhibitors for heart failure with reduced ejection fraction published inThe Lancet. This interview takes you through the key components of the meta-analysis: Forest plots, what to make of the heterogeneity of effect, and subgroup analyses.
SAMSON and the Future of Clinical Trials in Cardiology
The most interesting and impactful trial presented at the AHA this week (and simultaneously published in the New England Journal of Medicine) was the SAMSON trial,…
CVCT Global Forum Preview: One Patient Does Not Engagement Make
What is “patient engagement”? What does that really mean, and how can we ensure that patients are given opportunities to provide meaningful input into clinical trials?
Challenges in Minorities’ Participation in Clinical Trials: Feedback from the Participants
The minority population was 38% of the total U.S. population in 2014 and is expected to rise to 56% by 2060. Although minorities make up…
COVID-19 Lessons: How can we learn from our mistakes? What trials should we do?
Background The worldwide growth in coronavirus infections, followed by the WHO declaration of a global pandemic, led patients and government officials everywhere, concerned about serious…
Learning Amidst A Pandemic: Collecting COVID-19 Data Across Cardiovascular Clinical Trials
In December 2019, the rumblings of a virus meandering its way through Wuhan province in China slowly made their way to Western airways. Little attention…
More Controversy Over Major Cardiology Clinical Trial
Think about this: A new article reports that a major NIH-funded trial runs into trouble. The article raises all sorts of fundamental questions about our…
Cardiology World Erupts Into Controversy Over Change In Major Clinical Trial
As a major clinical trial in cardiology nears completion it has provoked a storm of criticism and controversy. The brouhaha erupted in response to a…
Moment Of Truth For Struggling And Expensive Cholesterol Drugs
It will be the moment of truth for the expensive new cholesterol drugs known as PCSK9 inhibitors. Next month we will learn much more about…
Clinical Trials: You Can’t Always Get What You Want
–Trial investigators have lost control of their trials’ messages. Editor’s Note: The following is a lightly edited version of a talk I presented (without slides!)…